Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies
7
0
0
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 7 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (7)
Establishment of the Human Intestinal and Salivary Microbiota Biobank - Obesity
Role: collaborator
Establishment of the Human Intestinal and Salivary Microbiota Biobank - Gastrointestinal Diseases
Role: collaborator
Establishment of the Human Intestinal and Salivary Microbiota Biobank - Gynecological Diseases
Role: collaborator
Establishment of the Human Intestinal and Salivary Microbiota Biobank - Oncologic Diseases
Role: collaborator
Establishment of the Human Intestinal and Salivary Microbiota Biobank - Kidney Diseases
Role: collaborator
Establishment of the Human Intestinal and Salivary Microbiota Biobank - Metabolic Syndrome
Role: collaborator
Establishment of the Human Intestinal and Salivary Microbiota Biobank- Diabetes
Role: collaborator
All 7 trials loaded